http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106414494-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate | 2014-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106414494-B |
| titleOfInvention | Human IgG1-derived antibody with pro-apoptotic activity |
| abstract | The present invention relates to methods for enhancing the therapeutic effect of human immunoglobulin G (IgG1) class 1 antibodies, derivatives or functional fragments thereof; antibodies or functional fragments thereof obtainable by such methods; and said antibodies or functional fragments thereof Use in therapy, the method comprises the steps of mutating the human CH1y1 domain from the antibody in order to restore the pairing between the CH1 and CL domains typical in other IgG subclasses, or by The CH1 domain of IgG2 (CH1y2), the CH1 domain of IgG3 (CH1y3), or the CH1 domain of IgG4 (CH1y4) replaces the human CH1y1 domain; the antibody comprises: a) a light chain comprising the following amino acid sequence: i ) a light chain variable region (LCVR) specific for an antigen; and ii) a human kappa constant (CL) region; and b) a heavy chain comprising the amino acid sequence of: i) a heavy chain variable region specific for the antigen Region (HCVR); ii) the CH2 and CH3 domains from human IgG1, and iii) the CH1 domain from human IgG1 mutated to restore the CH1 and CL domains typical in other IgG subclasses paired between, or replaced by CH1 domains from human IgG2, IgG3 or IgG4. |
| priorityDate | 2013-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.